InferVision Accelerates AI-Powered Clinical Research with the Appointment of Dr. Yun Shen and Launch of Global Clinical Collaboration Research Institute

Over the past year, Infervision’s first medical imaging product, InferRead CT Lung, has been successfully deployed in more than 250 top-tier hospitals worldwide. Through comprehensive refinement and iterative improvements during collaborative applications, the product’s robustness and ease of use have been significantly enhanced. It has not only received unanimous acclaim from users but also gradually become a valuable aid for physicians in auxiliary diagnosis.

Today, Infervision announced the establishment of the “iCR-InferVision Global Clinical Collaboration Research Institute” and invited Dr. Shen Yun, a top expert in the medical imaging field, to join Infervision as the Dean of the Institute and Chief Clinical Research Collaboration Scientist. This move launches Infervision’s global research strategy, strengthens its presence in the clinical research sector for medical imaging AI (artificial intelligence), and will further advance the development of clinical disciplines in medical AI.

Dr. Shen Yun, former Director and Chief Scientist of the GE Healthcare China CT Research Center (CTRC), holds a Ph.D. in Engineering and an M.D. He serves as a Visiting Lecturer at Tokyo Women’s Medical University and as a Tenured Research Professor at Shaanxi University of Chinese Medicine. In his early career, he was selected as a government-sponsored undergraduate student to study in Japan, where he enrolled in the Department of Electrical and Electronic Engineering at Nagoya University, completing his bachelor’s, master’s, and doctoral degrees. His specialization was plasma physics, with a primary research focus on using CT technology for diagnostics in controlled nuclear fusion. In April 1990, he joined GE (Japan), engaging in CT R&D and scientific collaborations for over 28 years. In 2005, he returned to China to establish the GE CTRC. Since 2006, he has led the CTRC scientific team in assisting GE CT users in publishing a total of 682 papers at the Radiological Society of North America (RSNA), averaging more than 50 publications per year. Since 2011, he has supported GE users in publishing over 250 SCI-indexed articles in prestigious international journals. Dr. Shen has developed unique models and theories for scientific collaboration, establishing standards for CT research, and holds a prominent position and significant influence in the medical imaging communities of both Japan and China.

During the interview, Dr. Shen Yun explained his reasons for joining Infervision: “AI has become a key national policy priority for the Chinese government. In the current landscape of AI in healthcare, it is still quite common that healthcare professionals lack sufficient understanding of AI, while AI experts often lack medical knowledge. I believe that my nearly 30 years of R&D experience in medical devices at GE Healthcare, particularly in scientific research collaborations, will help Infervision truly delve into clinical practice to understand physicians’ needs and determine how best to support them. Meanwhile, there is a notable shortage of rigorous clinical validation studies for AI products. Through the newly established iCR, we aim to launch extensive and in-depth clinical research collaborations with users, enabling more Chinese users to publish papers in renowned domestic and international academic journals and at conferences, thereby continuously enhancing their academic reputation both in China and abroad.”

Mr. Chen Kuan, Founder and CEO of Infervision, stated: “The newly established iCR by Infervision will continue to uphold the philosophy of ‘derived from clinical practice, applied back to clinical practice.’ With a core focus on serving clinical customers, and in collaboration with the Infervision Advanced Research Institute, we will closely integrate AI technological innovation with medical clinical practice, deeply explore the application value of artificial intelligence in clinical medical imaging, and lead the AI+healthcare industry to new heights.”

Over the past year, Infervision has leveraged visual deep learning data analysis tools to integrate artificial intelligence into the field of clinical research. In addition to having multiple abstracts accepted by the Radiological Society of North America (RSNA) and the European Congress of Radiology (ECR), the company has published several SCI-indexed research papers on AI in medical imaging and has successfully secured multiple national fund projects in collaboration with its clients. The addition of Dr. Shen Yun and the establishment of the Infervision Clinical Research Collaboration Academy (iCR) will propel Infervision’s scientific research development strategy to new heights.

Recently, the Political Bureau of the CPC Central Committee held a group study session on artificial intelligence. The new generation of AI is flourishing globally, serving as a strategic technology leading this round of technological revolution and industrial transformation, with a strong "lead goose" effect that drives widespread spillover impacts. Infervision has mobilized its R&D, scientific research, and marketing teams as three powerful engines to spearhead industry leadership at an unprecedented pace. The company will continue to strengthen the development of technological applications, adhere to clinical demand-oriented innovation, fully leverage China’s vast medical data resources and large-scale market application advantages, and effectively translate clinical research into practical outcomes.